1. Home
  2. UTHR vs EXPD Comparison

UTHR vs EXPD Comparison

Compare UTHR & EXPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • EXPD
  • Stock Information
  • Founded
  • UTHR 1996
  • EXPD 1979
  • Country
  • UTHR United States
  • EXPD United States
  • Employees
  • UTHR N/A
  • EXPD N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • EXPD Oil Refining/Marketing
  • Sector
  • UTHR Health Care
  • EXPD Consumer Discretionary
  • Exchange
  • UTHR Nasdaq
  • EXPD Nasdaq
  • Market Cap
  • UTHR 14.4B
  • EXPD 15.5B
  • IPO Year
  • UTHR 1999
  • EXPD N/A
  • Fundamental
  • Price
  • UTHR $297.02
  • EXPD $115.63
  • Analyst Decision
  • UTHR Buy
  • EXPD Sell
  • Analyst Count
  • UTHR 13
  • EXPD 10
  • Target Price
  • UTHR $383.08
  • EXPD $113.78
  • AVG Volume (30 Days)
  • UTHR 551.5K
  • EXPD 1.1M
  • Earning Date
  • UTHR 07-30-2025
  • EXPD 08-05-2025
  • Dividend Yield
  • UTHR N/A
  • EXPD 1.33%
  • EPS Growth
  • UTHR 18.86
  • EXPD 27.66
  • EPS
  • UTHR 25.10
  • EXPD 6.03
  • Revenue
  • UTHR $2,994,100,000.00
  • EXPD $11,060,256,000.00
  • Revenue This Year
  • UTHR $14.30
  • EXPD $0.09
  • Revenue Next Year
  • UTHR $6.32
  • EXPD $1.60
  • P/E Ratio
  • UTHR $11.79
  • EXPD $19.21
  • Revenue Growth
  • UTHR 19.84
  • EXPD 24.07
  • 52 Week Low
  • UTHR $266.98
  • EXPD $100.47
  • 52 Week High
  • UTHR $417.82
  • EXPD $131.59
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 51.32
  • EXPD 50.82
  • Support Level
  • UTHR $286.68
  • EXPD $115.88
  • Resistance Level
  • UTHR $301.75
  • EXPD $121.69
  • Average True Range (ATR)
  • UTHR 6.73
  • EXPD 2.40
  • MACD
  • UTHR 1.81
  • EXPD 0.13
  • Stochastic Oscillator
  • UTHR 77.16
  • EXPD 38.00

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About EXPD Expeditors International of Washington Inc.

Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.

Share on Social Networks: